Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
TSHAthis companyTaysha Gene Therapies, Inc.	$4.43	-16.18×	7.12×	179.93×	-13.52×	-85.9%	100.0%	-1130.6%	-1115.3%	-44.1%	-34.9%	-5.3%	0.07×	2.8×	-1,753.94×	12.23×	0.0%	2	7.06	1	C-
ABEOAbeona Therapeutics Inc.	$2.80	3.93×	1.75×	47.95×	2.87×	-76.4%	73.7%	-1536.9%	1223.1%	44.7%	-44.0%	-30.2%	0.16×	-0.68×	-23.92×	6.93×	0.0%	2	-3.55	2	C
BNTCBenitec Biopharma Inc.	$9.28	-13.65×	3.52×	0×	-8.75×	-68.5%	0.0%	0.0%	0.0%	-25.7%	-28.8%	-2.7%	0×	3.53×	0×	34×	0.0%	1	43.49	2	C+
FDMT4D Molecular Therapeutics, Inc.	$12.59	-3.1×	0.86×	5.1×	-2.99×	-184.8%	91.1%	-187.2%	-164.4%	-27.7%	-30.2%	-25.1%	0.04×	0.29×	0×	9.39×	0.0%	3	1.71	2	C
NGNENeurogene Inc.	$26.18	-4.86×	1.65×	0×	-3.92×	-83.6%	0.0%	0.0%	0.0%	-34.1%	-37.5%	-18.0%	0.04×	1.08×	-20,641.6×	16.56×	0.0%	1	6.39	2	C
PASGPassage Bio, Inc.	$3.80	-0.82×	2×	0×	-0.34×	101.7%	0.0%	0.0%	0.0%	-242.7%	-100.9%	-84.2%	1.28×	0.5×	0×	2.07×	0.0%	1	-43.91	2	C
Peer median	—	-3.1×	1.75×	0×	-2.99×	-76.4%	0.0%	0.0%	0.0%	-27.7%	-37.5%	-25.1%	0.04×	0.5×	0×	9.39×	0.0%	1	1.71	2	—